Trademark: 79091998
Word
ACLARUSDX
Status Date
Monday, August 24, 2020
Registration Number
4024702
Registration Date
Tuesday, September 13, 2011
Filing Date
Tuesday, August 24, 2010
Published for Opposition
Tuesday, June 28, 2011
Cancellation Date
Monday, August 24, 2020
1 Chemical preparations and compositions, namely, nucleic acids attached to a solid medium, for industrial and scientific use; chemical fissile preparations for laboratory use; chemical fissile preparations for scientific research; chemical preparations for nucleic acids attached to a solid medium, other than for medical or veterinary purposes; biological preparations, other than for medical or veterinary purposes, namely, blood for enabling the quantification of nucleic acid content; chemicals for scientific use, other than for medical or veterinary purposes; chemical preparations or reagents for laboratory, namely, nucleic acid to screen and analyze gene expression, to identify therapeutic targets and products, and to conduct pharmacogenomic and genotoxicity research in the fields of pharmacology, food, chemistry, cosmetology, plant protection, and veterinary sciences; chemical preparations for scientific use, namely, nucleic acid libraries to screen and analyze gene expression, to identify therapeutic targets and products, and to conduct pharmacogenomic and genotoxicity research in the fields of pharmacology, food, chemistry, cosmetology, plant protection, and veterinary sciences; chemical preparations for scientific use, namely, DNA biochips for decoding genes affected by the Alzheimer's disease or revealing the transcriptomic signature of patients affected with Alzheimer's disease, and DNA chips to make visible and analyze gene expression in the fields of human and pharmacological medicine and veterinary science
5 Pharmaceutical preparations for treating neurodegenerative diseases, particularly Alzheimer's disease; diagnostic reagents and media for medical use, namely, reagents and media for use in testing blood biomarkers, to enable the identification of patients suffering from Alzheimer's disease or at risk of developing the disease and for enabling the identification of patients responding to specific treatments; acidic biological preparations and products for pharmaceutical purposes, namely, pharmaceutical preparations for diagnosing Alzheimer's disease; capsules for diagnostic tests and medicines sold empty; chemico-pharmaceutical preparations for diagnosing, preventing and treating Alzheimer's disease; biopharmaceutical preparations for diagnosing, preventing and treating Alzheimer's disease; chemicals for medical, pharmaceutical or veterinary purposes, namely, chemicals for diagnosing neurodegenerative diseases, especially Alzheimer's disease; medical and clinical diagnosis testing kits comprised of nucleic acid banks, nucleic acids on DNA chips and testing probes; DNA libraries and RNA libraries for medical diagnostic purposes; nucleic acid sequences for use on biochips, for medical and medical diagnostic use, namely, for decoding genes affected by Alzheimer's disease or revealing the transcriptomic signature of patients suffering from Alzheimer's disease; enzymes or enzyme preparations for medical or veterinary purposes, namely, enzyme stabilizers and enzyme substrates used as ingredients in medicines for treatment of Alzheimer's disease; reagents contained in diagnostic test kits for taking blood samples, for the preservation of the biological material under analysis in order to carry out the test under the appropriate conditions
10 Surgical, medical, dental and veterinary apparatus and instruments, namely, apparatus and instruments for use in identifying, assessing the seriousness of, assessing the prognoses of, measuring the progression of and measuring the conversion of neurodegenerative diseases such as Alzheimer's; medical apparatus using DNA chips for analyzing blood; apparatus for analyzing blood; apparatus for medical diagnostic purposes, namely, kits for taking blood samples comprising medical instruments for taking blood, DNA chips for diagnosing Alzheimer's disease, and material required for the preservation of the biological material under analysis in order to carry out the test under the appropriate conditions; spoons for medicines; containers specially adapted for the application of medicines, namely, bags and pouches used in the delivery of medication; probes for medical purposes; syringes for medical purposes; galvanic therapeutic devices for diagnosing neurodegenerative diseases, especially Alzheimer's disease
42 Research and development for others of pharmaceutical molecules or biological markers and medicines for diagnosing and treating neurodegenerative diseases; chemical analyses; chemical research; chemical services, namely, analysis of RNA genes, tissues, and blood samples; biotechnological project studies to identify people suffering from Alzheimer's disease and to measure the seriousness, prognoses, progression and conversion of the disease and to determine how patients respond to treatments; research and development of new products for others; biological research; biotechnological research; technical research in the field of biotechnology; biotechnological analysis services; laboratory analyses, namely, quantification of nucleic acid content for medical and scientific research purposes
44 Medical services; veterinary services; medical assistance; consulting in the fields of biotechnology and pharmacy, namely, to assist in the selection of Alzheimer's sufferers for clinical trials and to offer personalized treatments; hospitals; pharmacist's services to make up prescriptions; pharmaceutical advice; medical services, namely, facilitating the diagnosis and care of geriatric patients and patients with neurodegenerative diseases; health care; telemedicine services
The color(s) red and blue is/are claimed as a feature of the mark.
The mark consists of the wording "ACLARUSDX", with "ACLARUS" in blue and "DX" in red".
ACLARUS DX
Sep 10, 2021
Notification Of Effect Of Cancellation Of Intl Reg Mailed
Sep 10, 2021
Death Of International Registration
Sep 25, 2015
Total Invalidation Processed By The Ib
Sep 2, 2015
Total Invalidation Of Reg Ext Protection Sent To Ib
Sep 2, 2015
Invalidation Processed
Aug 5, 2015
Total Invalidation Of Reg Ext Protection Created
Dec 5, 2014
Cancelled Section 7-Total
Dec 5, 2014
Cancellation Terminated No. 999999
Dec 3, 2014
Cancellation Denied No. 999999
Oct 24, 2014
Cancellation Instituted No. 999999
May 19, 2013
Final Decision Transaction Processed By Ib
Dec 23, 2011
Final Disposition Notice Sent To Ib
Dec 23, 2011
Final Disposition Processed
Dec 13, 2011
Final Disposition Notice Created, To Be Sent To Ib
Oct 15, 2011
Change Of Name/Address Rec'd From Ib
Sep 13, 2011
Registered-Principal Register
Jun 28, 2011
Official Gazette Publication Confirmation E-Mailed
Jun 28, 2011
Published For Opposition
May 26, 2011
Law Office Publication Review Completed
May 26, 2011
Assigned To Lie
May 12, 2011
Approved For Pub - Principal Register
May 12, 2011
Examiner's Amendment Entered
May 12, 2011
Notification Of Examiners Amendment E-Mailed
May 12, 2011
Examiners Amendment E-Mailed
May 12, 2011
Examiners Amendment -Written
Apr 26, 2011
Teas Change Of Correspondence Received
Apr 26, 2011
Teas/Email Correspondence Entered
Apr 26, 2011
Correspondence Received In Law Office
Apr 26, 2011
Teas Response To Office Action Received
Feb 27, 2011
Refusal Processed By Ib
Feb 9, 2011
Non-Final Action Mailed - Refusal Sent To Ib
Feb 9, 2011
Refusal Processed By Mpu
Feb 9, 2011
Non-Final Action (Ib Refusal) Prepared For Review
Feb 8, 2011
Non-Final Action Written
Feb 8, 2011
Application Filing Receipt Mailed
Feb 4, 2011
Assigned To Examiner
Feb 4, 2011
New Application Office Supplied Data Entered In Tram
Feb 3, 2011
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
